Colloidal Oatmeal use in Dermatology (Supplement)
There is mounting evidence that colloidal oatmeal can safely enhance skin hydration and even help resolve clinical lesions through anti-inflammatory effects and by modulation of the microbiome.
CaSMO Management of Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: A Practical Primer
The management of cirAEs starts with physician awareness and patient education on the occurrence of toxicities, preventive measures, and skincare using gentle cleansers, moisturizers, and sunscreen started before immunotherapy begins and ongoing thereafter as part of the lifestyle.
Casmo Algorithm for Management of Hormonal Therapy-Related Cutaneous Adverse Effects in Oncology Patients
Breast and prostate cancer patients frequently use hormonal therapy to improve treatment outcomes and survival. However, these medications can be associated with numerous dermatologic adverse effects.
Understanding Psoriasis: Insights from Les Journées Dermatologiques de Paris
Drs. Joël Claveau & Julien Ringuet, two Canadian dermatologists with prominent clinical and research practices, attended the Les Journées Dermatologiques de Paris conference in Nov-Dec 2022, with a focus on presentations and posters about psoriasis. This article reviews key insights they obtained at the meeting.
Racial/Ethnic Variations in the Skin Barrier of Canadians: Implications for Skincare Recommendations Promoting a Healthy Skin Barrier and Mitigation of Atopic Dermatitis
Skin barrier differences and variations in the presentation of common dermatoses such as xerosis and atopic dermatitis (AD) have been reported in racial/ethnic Canadian patients. This review discusses skin barrier differences and explores the role of ceramide-containing skin care in promoting a healthy skin barrier and mitigating AD.
Review of Dermato-Surgery Peri-Procedure Care Promoting Wound Healing
Peri-procedural measures in dermato-surgery depend on patient factors and procedure type. Standardized guidelines support healthcare providers in optimizing outcomes, preventing infection, and reducing recovery time. Research is needed to evaluate purpose-designed moisturizers for post-procedural application and improving patient outcomes.
Managing Psoriasis with Topical Agents – Where Do We Stand?
Psoriasis vulgaris is a chronic, immune-mediated inflammatory skin disease affecting 2-4% of the Canadian population. While most psoriasis vulgaris cases are mild-to-moderate (>80%) and do not require systemic treatment, these cases can still be particularly challenging to treat as topical therapies present limitations, including efficacy and administration, leading to poor long-term treatment compliance and unsatisfactory treatment responses. The intent of this paper is to provide physicians with a clinically relevant review of the currently available and newly developed topical therapies...
Casmo Prevention and Management of Four Common Cutaneous Toxicities Associated with Targeted Cancer Therapies: Papulopustular Eruption, Xerosis, Paronychia, and Hand-Foot Skin Reaction
Advances in cancer treatment have contributed to a reduction in mortality but survivors and healthcare providers should be aware of the potential adverse effects of these advanced treatments.
Real-World Insights from Atopic Dermatitis Patients Treated with Abrocitinib
This real-world case series intends to illustrate a variety of moderate-to-severe AD patient cases to help guide discussions around abrocitinib and describe its treatment strategies used by experts in the field.
Protected: What’s New in Pre-Aging Topical Modalities: The Clinical Efficacy of Acetyl Dipeptide-31 Amide
Santina Conte MD1, Monica K. Li MD FRCPC FAAD2
1Division of Dermatology, McGill University, Montreal, Quebec, Canada
2Department of Dermatology and Skin Science, University of British...
Real World Canadian Case Series: Use of Tildrakizumab for Moderate-to-Severe Psoriasis
Psoriasis vulgaris, or plaque psoriasis, is a chronic systemic inflammatory disease characterized by scaly,
erythematous plaques. It is associated with comorbidities such as cardiovascular disease, metabolic syndrome, depression, and
anxiety, signifi cantly aff ecting patients' quality of life. Tildrakizumab, an IL-23 inhibitor, is approved for treating adults with
moderate-to-severe plaque psoriasis.